[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"walled-off-pancreatic-necrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:walled-off-pancreatic-necrosis":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100558632","necrosectomy-with-cryotechnology-for-accelerated-removal-100558632",false,"NCT06553651","Necrosectomy With Cryotechnology for Accelerated Removal","NECTAR","Inclusion Criteria:\n\n* Subjects aged 18 years and above, inclusive of both males and females.\n* Patients with symptomatic pancreatic necrosis resulting from acute pancreatitis, indicated for endoscopic necrosectomy following endoscopic ultrasound (EUS)-guided drainage.\n* Imaging indicative of ≥30% necrotic material within the pancreas.\n* Walled-off pancreatic necrosis (WOPN) size ≥6 cm.\n* Subjects able to tolerate repeated endoscopic procedures.\n* Capacity for providing informed consent.\n* Understanding of study requirements, provision of written informed consent, and willingness and ability to attend required follow-up assessments through 21 (+\u002F- 7) days.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Unwillingness to undergo repeated endoscopies.\n* Presence of documented Pseudoaneurysm \\> 1cm within the WOPN.\n* Intervening gastric varices or unavoidable blood vessels within the access tract.\n* Use of dual antiplatelet therapy or therapeutic anticoagulation that cannot be temporarily discontinued.\n* Any condition deemed by the investigator to compromise the safety of undergoing an endoscopic procedure.\n* Pregnancy, lactation, or absence of reliable contraception in women of childbearing potential.\n* Current enrollment in another investigational trial with potential to interfere with this study's endpoint analyses.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","Pancreatic necrosis is a serious complication of acute pancreatitis. Pancreatic necrosis involves the irreversible death of pancreatic tissue, which can lead to severe health issues, including infections and an increased risk of death. An endoscopic procedure called direct endoscopic necrosectomy (DEN) is typically performed to remove this necrotic pancreatic tissue as a minimally invasive treatment. This procedure is performed using a thin, flexible, lighted tube called an endoscope and endoscopic instruments that are used with working channels through the scope. Current methods for removing necrotic tissue involve using endoscopic devices such as snares, baskets, nets, and forceps. However, these standard methods are often not very effective because the necrotic tissue can be sticky and hard to grasp. This DEN procedure is part of regular clinical care to treat this condition and remove necrotic tissue from the pancreas.\n\nFor this research study, the same DEN procedure will be followed with the exception of the device used for the removal of the necrotic tissue. Instead of using forceps, snares, or other traditional tools, a cryoprobe will be used. Cryoprobes work by using extremely cold temperatures to freeze and adhere to the necrotic tissue, making it easier to remove. This method might be better because it can secure larger tissue samples and potentially reduce complications associated with traditional methods. Cryotechnology is successfully used in endoscopy to remove necrotic tissue, foreign bodies and more, but has not been extensively tested in pancreatic necrosis. Cryoprobes are FDA approved medical devices with an established safety record. They are used successfully in very sensitive areas such as the lungs. This study aims to evaluate the safety and effectiveness of cryotechnology for DEN.",[26,27,28,29,30,31],"Pancreatic Necrosis","Acute Pancreatitis","Acute Pancreatic Necrosis","Necrosis","Necrosis Pancreas","Walled-Off Pancreatic Necrosis",[33,34,35,36,37,38],"Direct Endoscopic Necrosectomy (DEN)","Endoscopic Necrosectomy","Pancreatic Necrosectomy","Necrosectomy","Cryotherapy","Cryotechnology","RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-25","ACTUAL",{"date":45,"type":20},"2026-12",{"date":47,"type":20},"2029-06",{"name":49,"class":50},"Christopher C. Thompson, MD, MSc","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100623372","nasojejunal-feeding-versus-oral-feeding-following-endoscopic-drainage-of-walled-off-pancreatic-necrosis-100623372","NCT07395778","Nasojejunal Feeding Versus Oral Feeding Following Endoscopic Drainage of Walled Off Pancreatic Necrosis","Nasojejunal Feeding Versus Oral Feeding Following Endoscopic Drainage of Walled Off Pancreatic Necrosis: A Randomized Controlled Pilot Study","Inclusion Criteria:\n\n1. Patients of acute pancreatitis (AP) with 18-75 years of age\n2. Patients with symptomatic WON requiring EUS guided transluminal drainage\n3. Provision of written informed consent\n\nExclusion Criteria:\n\n1. Patients with collection not amenable for EUS guided drainage (distance of WON \\>1 cm from the gastrointestinal lumen)\n2. Known malignancy or immunocompromised state\n3. Previous upper gastrointestinal(GI) surgery interfering with absorption\n4. Active GI bleeding\n5. GI obstruction, ileus or persistent vomiting\n6. Patients moribund to undergo endoscopic procedure (Glasgow coma scale \\\u003C8 or patients on ventilatory support)\n7. Patients with irreversible coagulopathy like platelets \\\u003C50,000\u002Fmm3 and\u002For INR\\>1.5\n8. Pregnant or lactating female","75 Years",{"count":61,"type":20},50,[23],"The goal of this randomized control trial is to assess whether nasojejunal feed is better than oral nutrition in patients who are undergoing endoscopic cystogastrostomy of walled off necrosis following acute pancreatitis. It will also try to answer, the incidence of infections and feed tolerance.\n\nThe main question it tries to answer is\n\n1. whether nasojejunl feed is better than oral feed in patients undergoing endoscopic cystogastrostomy in walled off necrosis following acute pancreatitis\n2. How much infections they develop, whether they are able to tolerate the feed, weight gain and reintervention rates in each group",[65,66,67],"Walled Off Pancreatic Necrosis","Acute Pancreatitis (AP)","Endoscopic Ultrasound-Guided Drainage",[69],"Cystogastrostomy, Walled off pancreatic necrosis, nutrition","2026-01-31",{"date":72,"type":43},"2026-02-09",{"date":74,"type":43},"2025-10-18",{"date":76,"type":20},"2027-01",{"name":78,"class":50},"Post Graduate Institute of Medical Education and Research, Chandigarh",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":51},"100603084","bedside-monitoring-of-microenvironmental-changes-in-infected-pancreatic-collections-100603084","NCT07131917","Bedside Monitoring of Microenvironmental Changes in Infected Pancreatic Collections","Feasibility, Safety and Clinical Impact of Bedside Microenvironmental Monitoring in Infected Walled-Off Pancreatic Necrosis During Standard Percutaneous Drainage","WOPN-MONITOR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of walled-off pancreatic necrosis (WOPN) confirmed by imaging (CT, MRI, or EUS)\n* Clinical suspicion or confirmation of infection in WOPN (e.g., fever, elevated inflammatory markers, positive culture)\n* Planned percutaneous drainage as part of standard care\n* Ability to provide informed consent (or surrogate consent where applicable)\n\nExclusion Criteria:\n\n* Coagulopathy not correctable prior to intervention (e.g., INR \\> 2.0 or platelets \\\u003C 50×10⁹\u002FL)\n* Known allergy or hypersensitivity to materials used in the monitoring probe\n* technical limitations precluding safe probe insertion",{"count":19,"type":20},[23],"This pilot clinical study aims to assess the feasibility and clinical relevance of bedside monitoring of microenvironmental conditions within infected walled-off pancreatic necrosis (WOPN).\n\nWOPN is a serious complication of acute pancreatitis, often associated with infection, organ failure, and the need for drainage or surgical intervention. Although infection is a key factor in prognosis, little is known about the local chemical environment inside the infected collections.\n\nIn this study, a sterile, miniaturized probe will be temporarily introduced into the necrotic cavity during standard percutaneous drainage. The goal is to record local microenvironmental parameters (such as acidity or related values) and monitor their changes over time.\n\nBy comparing these values with clinical data (e.g., inflammatory markers, microbiology, need for surgery), the study aims to determine whether such measurements can provide additional information about infection severity and treatment response.\n\nThe study does not involve any experimental treatment. All patients will receive standard medical care, including antibiotics, imaging, and drainage according to international guidelines.\n\nParticipation is voluntary. Only patients who provide informed consent will be enrolled.",[91,65],"Pancreatitis",[93],"pancreatitis","NOT_YET_RECRUITING","2025-08-13",{"date":97,"type":43},"2025-08-20",{"date":99,"type":20},"2025-11-01",{"date":101,"type":20},"2026-06-15",{"name":103,"class":50},"Martin Harazim"]